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Abstract
Smoking rates are particularly high during adolescence and young adulthood, when the brain is 
still undergoing significant developmental changes. Cross-sectional studies have revealed altered 
brain structure in smokers, such as thinner frontal cortical areas. Attention-deficit/hyperactivity 
disorder (ADHD) increases the risk of becoming nicotine-dependent, and has also been associated 
with abnormalities in frontal gray matter structure. The present study examines the relationships 
between smoking, cortical thickness and ADHD symptoms in a longitudinal design that compares 
adolescent and young adult smokers (n=44; 35 ADHD-affected) and non-smokers (n=45; 32 
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ADHD-affected) on frontal cortical thickness. Average frontal cortical thickness was estimated 
through structural magnetic resonance imaging at two time points (mean ages 17.7 and 21.1 
years), on average 3.4 years apart. Smokers had a 2.6% thinner frontal cortex than non-smokers 
and this effect was not explained by ADHD or other confounding factors. The rate of cortical 
thinning across the 3.4-year MRI measurement interval was similar in the total group of smokers 
compared to non-smokers. However, speeded thinning did occur in smokers who had started 
regular smoking more recently, in between the two measurements. These novel regular smokers 
did not differ significantly from the non-smokers at baseline. This suggests that the thinner frontal 
cortex was not a predisposing factor but rather a consequence of smoking. Although smokers had 
more ADHD symptoms overall, smoking did not influence the developmental course of ADHD 
symptoms.
Keywords
Tobacco; Smoking; Attention Deficit-Hyperactivity Disorder; Magnetic Resonance Imaging; 
Frontal Cortex; Longitudinal Studies
Introduction
Smoking rates are particularly high during adolescence and young adulthood, when the brain 
is still undergoing significant developmental changes (Lydon et al., 2014). The presence of 
attention-deficit/hyperactivity disorder (ADHD) increases the risk of becoming nicotine-
dependent (Groenman et al., 2013; Lee et al., 2011). In the current study, we examined the 
interplay between tobacco smoking, brain development, and ADHD symptoms by 
investigating the longitudinal effect of smoking on thickness of the frontal cortex in 
adolescents and young adults with and without ADHD.
Several structural magnetic resonance imaging (sMRI) studies have explored links between 
smoking and deviations in cortical gray matter structure. A recent meta-analysis on studies 
using voxel-based morphometry (VBM) revealed that smokers had smaller gray matter 
volumes bilaterally in the frontal cortex and larger volumes in the right lingual cortex 
(Zhong et al., 2016). Other studies used cortical thickness (CT) as an outcome measure, 
which has been argued to be a more specific and sensitive measure for gray matter loss than 
VBM (Kühn et al., 2010). In accordance with the VBM studies, smokers exhibited lower CT 
in the orbitofrontal cortex (OFC), anterior cingulate cortex (ACC), and insula, and also more 
extensively across the frontal, temporal and parietal lobes (Durazzo et al., 2013; Karama et 
al., 2015; Kühn et al., 2010; Li et al., 2015). Taken together, less gray matter in various brain 
regions has been observed in relation to smoking, but most consistently in the prefrontal 
cortex (Wang et al., 2015).
Due to a lack of longitudinal studies it remains unclear whether the thinner frontal gray 
matter in smokers represents a pre-existing difference, making individuals more prone to 
develop smoking habits, or is a consequence of tobacco exposure. Only three longitudinal 
studies have been performed to date, all in middle-aged and elderly populations. Two of 
these studies investigated global gray matter volume and detected no accelerated volume 
loss in smokers over a period of four or five years respectively (Duriez et al., 2014; Van 
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Haren et al., 2010). One study looked at regional volumes, demonstrating that elderly 
participants with a lifetime history of smoking displayed faster atrophy over two years in the 
OFC, middle frontal gyrus, and other frontal regions, as well as posterior and paralimbic 
areas (Durazzo et al., 2012). The above stresses the need for more longitudinal studies, 
especially in adolescence and young adulthood, the sensitive period in brain development 
when smoking habits are formed.
Here, we describe a study investigating longitudinal effects of smoking on the development 
of frontal cortex in adolescents with and without ADHD. The prefrontal cortex is among the 
last brain regions to mature and is thought to play a crucial role in exerting cognitive control 
over behaviour (Casey et al., 2005). It has been hypothesised that immature cognitive control 
abilities make adolescents and young adults more prone to drug use (Loth et al., 2011), and 
deficits in cognitive control have been associated with ADHD (Lee et al., 2011; Lipszyc and 
Schachar, 2010). These deficits in cognitive control coincide with the presence of smaller 
frontal volumes (of for example the OFC and ACC) in individuals with ADHD (Bralten et 
al., 2016; Frodl and Skokauskas, 2012; Valera et al., 2007). Accordingly, decreased CT in 
frontal areas may be a shared predisposing factor of individuals with ADHD and smokers, 
and may reflect immature cognitive control abilities.
To disentangle cause and consequence in the relation of smoking and CT, our first aim was 
to capture the progressive effect of smoking on frontal CT through adolescence and young 
adulthood, while controlling for ADHD as an alternative explanation.
As our second aim, we explored whether associations of smoking with frontal CT 
development depended on ADHD severity. We hypothesised that, considering the already 
vulnerable frontal cortical structure as reported in ADHD, smoking would have a larger 
impact on the frontal CT of individuals with more severe ADHD.
If smoking indeed speeds up thinning of the frontal cortex, this could in turn influence the 
development of ADHD symptoms. While smoking may have beneficial acute effects on 
ADHD symptoms (Gehricke et al., 2007), potentially used for self-medication purposes, it 
has been proposed that long-term smoking may cause amplification of impulsive behaviour 
(DeBry and Tiffany, 2008). Due to the lack of longitudinal studies, this hypothesis has been 
left largely unexplored. Therefore, our third aim was to investigate whether the 
developmental course of ADHD symptoms was different in smokers relative to non-
smokers.
Experimental procedures
Participant selection
Participants were part of a longitudinal cohort study starting in 2003 (International 
Multicenter ADHD Genetics study; Müller et al., 2011), consisting of participants originally 
recruited with an ADHD diagnosis (probands), their affected or unaffected siblings, and 
healthy controls. A structural MRI scan was collected during the NeuroIMAGE follow-up 
study (T1; 2009–2012; von Rhein et al., 2015) and subsequently during the NeuroIMAGE II 
follow-up study (T2; 2013–2015). We identified smokers and non-smokers in this cohort 
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based on self-reported tobacco use at T2. More specifically, smokers confirmed to smoke 
regularly (daily or a couple of times a week) now, or to have smoked regularly in the past 
year. Smokers reporting quit attempts were included; only two reported to have recently quit 
successfully at T2. Non-smokers had to be free of any indication of present or past regular 
smoking (monthly or more frequently). Smokers and non-smokers groups both included 
probands, affected and unaffected siblings, and healthy controls. The non-smokers were 
matched as closely as possible to the smokers on number of ADHD-affected and -unaffected 
participants, gender, age, and IQ with the package MatchIT (Ho et al., 2011) in R. IQ was 
estimated using the vocabulary and block design subtests of the Wechsler Intelligence Scale 
for Children (WISC-III; Wechsler, 2002) or Wechsler Adult Intelligence Scale (WAIS-III; 
Wechsler, 2000), obtained during T1 and T2. Characteristics of the resulting groups of 44 
smokers and 45 non-smokers are displayed in Table 1. These groups did not differ 
significantly in the proportion of ADHD-affected participants as established by a Chi-square 
test; smokers, 79.5%, non-smokers, 71.1%, χ2(1, N=89)=0.85, p=.356. More detailed 
information on participant selection and phenotypic information can be found in the 
Supplementary Information.
Phenotypic information
Diagnostic information—Diagnosis and symptom counts for ADHD and comorbid 
disorders were determined by semi-structured clinical interview at T1 and T2 (Schedule for 
affective disorders and schizophrenia for school-age children; Kaufman et al., 1997) and 
Conners’ ADHD questionnaires (Conners, 1998). A diagnosis of ADHD was given if the 
participant had 6 or more inattention and/or 6 or more hyperactivity-impulsivity symptoms 
according to DSM-IV criteria. Unaffected siblings and healthy controls were allowed a 
maximum of 3 symptoms overall. Siblings with subthreshold ADHD, who did not meet 
criteria for either ADHD or unaffected status, were included in the analysis and were also 
labelled ‘affected’ for the purpose of the matching procedure as described above. 
Throughout the remainder of the paper symptom count was used as a continuous measure 
for ADHD and no group comparisons of ADHD-affected versus ADHD-unaffected were 
made.
Smoking information—At T1 and T2, smoking was assessed with a self-report rating 
scale version of the antisocial behaviour interview (Loeber et al., 1989), which includes a 
question on frequency of tobacco use over the past half year (never, once or a few times, 
monthly, weekly, daily). During T2, the Fagerström Test for Nicotine Dependence 
(Heatherton et al., 1991) was also obtained with additional variables that were used for our 
classification: “Do you smoke regularly (daily or a couple of times per week) now, or did 
you smoker regularly in the past year?” and “At what age did you start smoking regularly?”.
Procedures
Details on ethics and procedures of the NeuroIMAGE (T1) study can be found in von Rhein 
et al. (2015). The procedures of NeuroIMAGE II (T2) were approved by the regional ethics 
committee (Centrale Commissie Mensgebonden Onderzoek: CMO RegioArnhemNijmegen; 
2012/542; ABR: NL41950.091.12). Written informed consent was obtained from 
participants and/or their legal guardians depending on the age of the participant.
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Image acquisition and processing
MPRAGE T1*weighted structural scans were acquired on a 1.5 Tesla Siemens Avanto 
scanner (TR=2730 ms, TE=2.95 ms, TI=1000 ms, voxel size=1×1×1 mm, FOV=256 mm, 
176 slices). The same scanner and protocol was used for T1 and T2. The following steps 
were undertaken for these studies separately. Structural scans were processed in the 
automatic segmentation toolbox FreeSurfer (http://surfer.nmr.mgh.harvard.edu) to obtain 
estimates of regional CT and surface area. An aggregate measure of frontal CT was 
computed by averaging the CT estimates of the following regions (left and right), weighted 
by the respective surface areas of those regions: caudal anterior cingulate, rostral anterior 
cingulate, caudal middle frontal, rostral middle frontal, lateral orbitofrontal, medial 
orbitofrontal, superior frontal, pars opercularis, pars orbitalis, pars triangularis, frontal pole 
and insula (see Figure 1). Visual inspection was performed on all subjects’ internal and 
external surface views for evident segmentation errors in the above regions. Following 
inspection, we concluded that frontal CT could be estimated correctly for all participants.
Analysis aims 1 and 2: Effect of smoking on frontal cortical thickness development
To investigate whether the development of frontal CT was different in smokers compared to 
non-smokers (the groups as described in Table 1), we set up a ‘main model’ using linear 
mixed-effects modelling with the lme4 package (Bates et al., 2015) in R (see supplement for 
details and model statement). This method was chosen, as opposed to the more traditional 
repeated measures analysis of variance (ANOVA), to account for the familial dependence in 
the data and for the fact that ADHD symptom count and diagnostic status may vary over 
time. With an ANOVA, fixed groups would have to be used. For the main model, we used 
the aforementioned composite measure of frontal CT as a within-subject dependent variable, 
with repeated measures at T1 and T2. To examine whether smokers differed in development 
of frontal CT compared to non-smokers, we specified a fixed effect for the interaction 
between smoking (smokers vs. non-smokers) and age (age was used as the within-subject 
time variable). Main effects of smoking and age were also included. These main effects 
captured time-independent differences between smokers and non-smokers, and general 
development of frontal CT, respectively. Since there is strong evidence that CT declines 
linearly in our age range of 9.5 to 27.6 years (Raznahan et al., 2011; Wierenga et al., 2014), 
we did not model quadratic effects of age. To model associations with ADHD symptoms 
within the main model, a fixed effect was included for symptom count (within-subject 
repeated measures), plus all possible interactions. All continuous predictors were mean-
centred before entering the model. Random intercepts were modelled to account for within-
subject dependence (repeated measures) and within-family dependence in CT. Random 
slopes, to capture variability in CT change over time per participant and per family, could 
not be modelled given that we only had 2 observations. The significance threshold was set at 
p≤.05, and where relevant, we obtained values for adjusted means of effects and marginal 
pseudo R2 (variance explained by fixed effects). In the supplement, sensitivity analyses are 
described, checking the robustness of the results of the main model. These concern an 
analysis after the removal of influential cases and analyses controlling for the potentially 
confounding effects of gender, estimated IQ, socio-economic status, intra-cranial volume, 
alcohol use, other drug use, oppositional defiant (ODD) and conduct disorder (CD) 
symptoms, anxiety and depressive disorders, and medication use. Finally, a supplemental 
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analysis was performed in ADHD-affected participants only, to see whether the effect was 
present within this clinically relevant subgroup and to further confirm that the effect was not 
driven by affected/unaffected status.
Analysis aim 3: Effect of smoking on ADHD symptom development
To examine the influence of smoking on ADHD symptom development, a model was 
estimated with symptom count as the within-subject dependent variable and smoking, age 
and smoking × age as fixed factors (see supplement for model statement). A robustness 
check for this analysis is detailed in the supplement. To explore whether effects on symptom 
count were driven by a specific symptom domain, models were also estimated for inattention 
symptoms and hyperactivity-impulsivity symptoms separately.
Post hoc analysis of onset of regular smoking
As a post hoc question, we were interested whether smoking onset and duration had an 
effect on our findings. Specifically, we were interested in separating smokers who started 
regular smoking before T1, from smokers who did not smoke regularly yet at T1, but started 
in between T1 and T2. Separating these groups sheds more light on the question whether 
differences in brain structure were already present before smoking onset or are more likely 
to be a consequence of regular smoking. To assess whether smokers who started regular 
smoking after T1 already had a thinner frontal cortex compared to non-smokers at that time 
point, we estimated a model for T1 with a fixed factor for smoking, consisting of the 
categories ‘non-smokers’, ‘onset before T1’, and ‘onset after T1’. We further added the 
following fixed effects: age, symptom count, and all two-way interactions among these fixed 
effects. In the event of a significant effect of the smoking onset categories, post hoc pairwise 
comparisons were performed with Tukey’s correction for multiple comparisons between the 
three groups. In addition, to test for differences between the groups in the developmental 
slope of frontal CT, a model including both time points was specified (similar to the 
abovementioned main model). For completeness, pairwise comparisons at T2 are also 
reported.
Post hoc analysis of regional specificity
Post hoc tests were conducted to explore whether an effect was driven by specific frontal 
regions, or was seen more globally across the frontal cortex. To this end, the main model 
was estimated for the CT obtained for each of the frontal regions separately. We also looked 
at the possibility of a whole-brain effect by using total CT, across the whole brain, as an 
outcome measure. Since this analysis concerns post hoc exploration of the magnitude of 
effect per region, results focus on the coefficients of the smoking effect and their standard 
errors. For completeness, uncorrected p-values are presented for the effect of smoking per 
region, but are not interpreted. To enable comparison of findings with two longitudinal 
studies described in the introduction (Duriez et al., 2014; Van Haren et al., 2010), the 
supplement includes an additional analysis with total gray matter volume as the outcome 
measure.
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Results
Aims 1 and 2: The effect of smoking on frontal cortical thickness development
Smokers had a 2.6% thinner frontal cortex compared to non-smokers. This main effect of 
smoking was significant (F(1, 92.1)=14.2, p<.001; coef=−0.035, SE=0.009). Additionally, 
there was a significant main effect of age (F(1, 156.1)=69.2, p<.001; coef=−0.014, 
SE=0.002), with a 2.6% reduction in frontal CT per 5 years of aging. These effects are 
shown in Figure 2. Moreover, Figure 2 shows that smokers did not differ in the rate of 
frontal cortical thinning over time relative to non-smokers, i.e., the interaction between 
smoking and age was not significant (F(1, 155.2)=0.003, p=.955). The main effect of 
symptom count contributed significantly to the model (F(1, 162.4)=6.35, p=.012; 
coef=0.003, SE=0.001). However, it must be noted that this effect was very small; the 
adjusted means showed an increase of 0.006% in frontal CT per additional 5 symptoms. We 
therefore chose not to interpret this effect further. The following effects included in the 
model were not significant: smoking × symptom count (F(1, 150.0)=0.45, p=.503), age 
×symptom count (F(1, 134.3)=2.96, p=.088), and smoking × age × symptom count (F(1, 
135.9)=0.55, p=.461). Together, all fixed factors in the main model explained 38.6% of the 
variance in frontal CT (marginal pseudo R2).
Sensitivity analyses—In the supplement, we describe sensitivity analyses in which we 
examined the potentially confounding effects of gender, estimated IQ, socio-economic 
status, intra-cranial volume, problematic alcohol use, regular other drug use, ODD and CD 
symptoms, anxiety and depressive disorders, and medication use. None of these variables 
significantly affected the reported main effect of smoking on frontal CT. Furthermore, the 
main effect of smoking remained significant after exclusion of influential cases and after 
running the model in ADHD-affected participants only.
Aim 3: Effect of smoking on symptom development
Smoking had no significant effect on the developmental course of ADHD symptom count 
(interaction of smoking with age; F(1, 142.6)=0.14, p=.708). Yet, smokers had on average 
more symptoms (adjusted mean 9.5) relative to non-smokers (adjusted mean 6.3) (main 
effect of smoking; F(1, 84.5)=7.86, p=.006; coef=1.58, SE=0.553). Age was also a 
significant predictor in the model (F(1, 140.1)=21.4, p<.001; coef=−0.42, SE=0.090); the 
symptom count declined with 2.1 per 5 years of aging. The main effect of smoking remained 
significant after exclusion of influential cases (see supplement for details). Separate models 
revealed that smoking significantly predicted inattention symptoms (p<.001), but not 
hyperactivity-impulsivity symptoms (p=.113). Aging affected both inattention symptoms 
(p<.001) and hyperactivity-impulsivity symptoms (p<.001). Effects are depicted in Figure 3.
Post hoc analysis of onset regular smoking
Smoking onset had an effect on CT at T1 (F(2, 72.4)=10.6, p<.001), which is depicted in 
Figure 4. Pairwise comparisons indicated that the ‘novel’ smokers, who started regular 
smoking after T1 (n =13), did not yet differ significantly from the non-smokers (n=45) at T1 
(t(79.0)=0.89, padj=.646); but at that time point, they did exhibit higher frontal CT estimates 
relative to the ‘long-term’ smokers, that had been smoking regularly since before T1 (n=31) 
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(long-term smokers estimated at 5.9% thinner; t(78.6)=2.51, padj=.038). By contrast, the 
long-term smokers already had a significantly thinner frontal cortex compared to the non-
smokers at T1 (estimated at 3.9% thinner; t(64.5)=4.32, padj<.001). In the developmental 
model including both time points, the interaction of the smoking onset categories with age 
was significant (F(2, 125.5)=3.07, p=.050). As can be seen in Figure 4, the decline in frontal 
CT with age seems steeper in the novel smokers compared to the other groups. At T2, the 
long-term smokers differed significantly (padj=.004) and the novel smokers non-significantly 
(padj=.832) from non-smokers, and the smoking groups did not differ from each other (padj=.
592). Sample characteristics for novel and long-term smokers, including available 
information on smoking behaviour, are displayed in Supplementary Table 1. We performed 
additional sensitivity analyses, described in the supplement, to account for potentially 
confounding differences between these groups. From these sensitivity analyses, we conclude 
that there may be some overlap between IQ (development) and CT development in the 
different groups. However, we cannot make claims on the causal direction of this effect and 
the possibility remains that smoking affects IQ via a reduction in CT.
Post hoc analysis of regional specificity
Table 2, containing the CT results per frontal region and for the total brain, shows that the 
highest t-values were observed in the right lateral and medial orbitofrontal cortices. The 
results from Table 2 reveal widespread effects across the frontal cortex and also at the total 
brain level. An additional analysis with total gray matter volume as opposed to CT as the 
outcome measure can be found in the supplement and yielded no evidence for an effect of 
smoking.
Discussion
The current study examined the interplay between tobacco smoking, brain development, and 
ADHD symptoms by investigating the longitudinal effect of smoking on frontal CT in 
adolescents and young adults with and without ADHD. Hereby, we attempted to disentangle 
cause and consequence in the relation of smoking and CT. We observed that smokers had a 
2.6% thinner frontal cortex than non-smokers, but we found no difference in rate of thinning 
across the 3.4-year MRI measurement interval. We conducted an additional analysis 
separating novel smokers, who started regular smoking after the baseline scan, from long-
term smokers, who had been smoking since before the baseline scan. This analysis revealed 
that the novel smokers were not significantly different from non-smokers at baseline, 
whereas the long-term smokers did already have a thinner frontal cortex compared to the 
non-smokers. Furthermore, our results suggested accelerated thinning in the novel smokers.
Our main finding of a thinner frontal cortex in smokers is in line with previous reports 
describing CT and volume differences between smokers and non-smokers (Durazzo et al., 
2013; Kühn et al., 2010; Li et al., 2015; Wang et al., 2015; Zhong et al., 2016). We also 
observed a relationship between smoking and total CT, which is in agreement with more 
widespread effects found in earlier studies (Wang et al., 2015). Of the frontal regions that we 
distinguished, the effect of smoking was strongest in the right orbitofrontal cortex (OFC). 
Notably, in two earlier studies, OFC volume correlated negatively with magnitude of 
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tobacco exposure, implying a dose-dependent effect (Kühn et al., 2010; Li et al., 2015). 
Smaller OFC volumes have also been linked to other forms of substance use (e.g., Lotfipour 
et al., 2009; Smith et al., 2015; Tanabe et al., 2009), and the role of the OFC in addiction is 
further substantiated by a myriad of functional neuroimaging findings showing that OFC 
activity varies with drug expectation, craving, and addiction severity (Goldstein and Volkow, 
2011; Jasinska et al., 2014).
Results of our post-hoc analyses suggest that the reductions in frontal CT observed in 
smokers were not yet present before the onset of regular smoking. We could not confirm 
accelerated thinning across the total group of smokers in our study, but the novel smokers 
exhibited a steeper decline in frontal CT with age compared to long-term smokers and non-
smokers. Although this result warrants replication due to the low number of novel smokers, 
we speculate that this difference between novel and long-term smokers could be due to one 
of the following reasons, or a combination thereof. First, the long-term smokers were older 
(mean age at T1 = 19.1 years) than the novel smokers (mean age at T1= 14.9 years), which 
could mean that the long-term smokers are more likely to have passed their most vulnerable 
period in adolescent brain development (Dwyer et al., 2009). Second, while the exact 
biological mechanisms by which tobacco smoke affects gray matter structure are unclear 
(Chang et al., 2014), these could include mechanisms (for example in the cerebrovascular 
system, cytoarchitecture, or synaptic functioning) that result in relatively steep changes in 
CT at first, but then become more stable. Our findings provide an important addition to the 
literature by contributing for the first time a longitudinal investigation in adolescents and 
young adults. This is crucial, since the neurotoxic effects of tobacco may depend on 
developmental stage (Dwyer et al., 2009). In one of the few previous longitudinal studies, 
elderly participants with a lifetime history of smoking displayed faster volume loss in 
several regions, among which the OFC, over two years (Durazzo et al., 2012). Two other 
studies, in middle-aged and elderly samples, did not observe associations of smoking with 
changes in global gray matter volume over periods of four and five years respectively 
(Duriez et al., 2014; Van Haren et al., 2010). This is perhaps not surprising, considering the 
fact that neurotoxic effects may vary between regions (Dwyer et al., 2009), with striatal 
regions often found to be unaffected or even larger in smokers (Das et al., 2012; Li et al., 
2015). In agreement with this, we found no significant effect of smoking on total gray matter 
volume. Our results imply that CT constitutes a measure that is more sensitive to the effects 
of smoking than global volume.
As our second aim, we explored whether the influence of smoking on frontal CT 
development depended on ADHD severity. We proposed that smoking would have a larger 
impact on the frontal CT of individuals with more severe ADHD, as they would have, 
according to the literature, an already vulnerable frontal cortical structure. The results 
provided no support for this hypothesis, but considering the small number of ADHD-
unaffected participants in our sample the power to detect such an interaction could have been 
limited. Smokers and non-smokers were matched on number of ADHD-cases, and in line 
with the previously established heightened prevalence of smoking in individuals with 
ADHD (Groenman et al., 2013), most of the smokers in our study were ADHD-affected 
participants. The matched group design optimised our ability to draw firm conclusions about 
the progressive effect of smoking on frontal CT, while controlling for ADHD as an 
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alternative explanation. Like smoking, ADHD has been related to thinner frontal cortical 
regions (e.g., Almeida et al., 2010; Fernández-Jaén et al., 2014; Makris et al., 2007; Silk et 
al., 2016), although not consistently (Dirlikov et al., 2015; Schweren et al., 2015). However, 
our results argue that smoking leads to accelerated thinning of the frontal cortex independent 
of ADHD. This underscores the importance of taking into account smoking habits when 
comparing individuals with ADHD, or other neuropsychiatric disorders with high smoking 
rates, to healthy controls.
Our third aim was to investigate whether smoking influenced the development of ADHD 
symptoms. We expected that if smoking speeded thinning of the frontal cortex, this could 
subsequently lead to exacerbation of ADHD symptoms. Although smokers had more ADHD 
symptoms overall, our results did not support a difference in the rate with which the number 
of ADHD symptoms declined in smokers relative to non-smokers. However, this seems in 
agreement with the fact that we did not find accelerated thinning of the frontal cortex across 
the whole group of smokers. It has been argued that neurobiological effects of smoking are 
likely to contribute to elevated levels of impulsivity seen in smokers, but due to the 
complexity of this research there is limited support for this theory (De Wit, 2008; DeBry and 
Tiffany, 2008). More prospective research is required to confirm that smokers show similar 
rates of ADHD remittance as non-smokers.
Our findings should be considered in the context of some strengths and limitations. First, 
although we could confidently capture the general contrast of regular smoking versus non-
regular smoking, we had limited opportunities to explore dose-dependent effects, since the 
NeuroIMAGE sample did not include precise measures on amount and frequency of 
smoking over time. Second, although two measurements over 3.4 years can already reveal 
valuable information regarding the progressive effect of smoking, studies with more time 
points and more sophisticated smoking measures are desired. This would further elucidate 
the causality question and allow for more precise mapping of trajectories of tobacco 
exposure onto the trajectories of CT development. Nevertheless, our study adds significantly 
to the literature by investigating for the first time the effect of smoking on frontal CT in 
adolescence and young adulthood using a longitudinal design. Furthermore, our design 
allowed us to examine the so far unexplored effect of smoking on ADHD symptom 
development. An additional strength of this study is the rigorous control for potentially 
confounding factors including: gender, estimated IQ, socio-economic status, intra-cranial 
volume, other drug use, ODD/CD symptoms, anxiety and depressive disorders, and 
medication use.
To conclude, we confirmed previous reports of a thinner frontal cortex in smokers, and 
showed that although smokers had more ADHD symptoms overall, smoking did not seem to 
influence the developmental course of ADHD symptoms. The results did not support an 
acceleration of frontal cortical thinning in the total group of smokers. However, post-hoc 
analyses were indicative of speeded thinning in novel regular smokers, who did not differ 
from non-smokers at baseline. This suggests that a thinner frontal cortex was not a 
predisposing factor but rather a consequence of smoking.
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Figure 1. Regions included in the frontal cortical thickness composite measure
Note: the composite measure of frontal cortical thickness was computed by averaging the 
cortical thickness estimates of the coloured regions (left and right) weighted by the 
respective surface areas of those regions. Segmentation was based on the FreeSurfer 
‘Desikan-Killiany’ atlas (https://surfer.nmr.mgh.harvard.edu/fswiki/CorticalParcellation).
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Figure 2. Development of average frontal cortical thickness in smokers and non-smokers
Note: figure displays raw means and SEs.
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Figure 3. Development of inattention and hyperactivity-impulsivity symptoms in smokers and 
non-smokers
Note: figure displays raw means and SEs.
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Figure 4. Development of average frontal cortical thickness in non-smokers, smokers that started 
regular smoking before T1 (long-term smokers), and smokers that started regular smoking after 
T1 (novel smokers)
Note: figure displays raw means and SEs.
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Table 1
Sample characteristics.
Smokers Non-smokers 1
 Difference test
n 44 45
Males, n 28 25 χ2(1)=0.60, p=.437
ADHD symptom count at T1, M (SD) 9.95 (5.85) 7.27 (5.60) t(87)=2.21, p=.029
2Age in years T1, M (SD) 17.9 (2.68) 17.6 (3.51) t(87)=0.49, p=.627
3Age in years T2, M (SD) 21.3 (2.83) 20.9 (3.52) t(87)=0.54, p=.590
Interval in years, M(SD) 3.42 (0.79) 3.37 (0.59) t(87)=0.29, p=.769
Estimated IQ T1, M (SD) 97.8 (15.4) 99.8(14.1) t(87)=0.67, p=.504
Estimated IQ T2, M (SD) 94.8 (16.0) 100.8 (16.1) t(87)=1.78, p=.079
4Used ADHD medication in past 5 years, n 20 20 χ2(1)=0.04, p=.846
5Indication of problematic alcohol use, n 10 6 χ2(1)=1.33, p=.249
5Indication of regular cannabis or other drug use, n 21 1 χ2(1)=24.8, p<.001
6, 7ODD/CD symptom count > 5, n 9 1
6, 7Anxiety disorder/depressive disorder, n 3/3 2/1
1
Differences between smokers and non-smokers were tested by means of independent samples t-tests or Chi-square tests of independence.
2
The age range at T1 was 9.5 – 24.2.
3
The age range at T2 was 12.9 – 27.6.
4
Reported at T2, see supplement for details.
5At any time point from initial inclusion, see supplement for details.
6
Reported at T1 or T2, see supplement for details.
7Chi-square tests could not be performed due to cells with a minimum expected frequency < 5.
Abbreviations: ADHD – attention-deficit/hyperactivity disorder, CD – conduct disorder, ODD – oppositional defiant disorder.
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Table 2
Effect of smoking on cortical thickness per frontal region and for the total brain.
Regional cortical thickness outcome coefficient smoking SE t-value p-value of smoking factor (uncorrected)
Left caudal anterior cingulate cortex −0.013 0.023 0.58 .569
Right caudal anterior cingulate cortex 0.009 0.022 0.39 .707
Left caudal middle frontal −0.031 0.012 2.54 .015
Right caudal middle frontal −0.038 0.014 2.72 .009
Left lateral orbitofrontal −0.042 0.014 2.98 .004
Right lateral orbitofrontal −0.050 0.014 3.51 < .001
Left medial orbitofrontal −0.048 0.016 3.03 .004
Right medial orbitofrontal −0.060 0.017 3.46 .001
Left pars opercularis −0.047 0.015 3.21 .002
Right pars opercularis −0.048 0.016 3.08 .003
Left pars orbitalis −0.050 0.018 2.75 .008
Right pars orbitalis −0.030 0.020 1.52 .141
Left triangularis −0.038 0.014 2.79 .008
Right triangularis −0.042 0.015 2.88 .006
Left rostral anterior cingulate cortex −0.033 0.024 1.37 .183
Right rostral anterior cingulate cortex −0.067 0.023 2.97 .005
Left rostral middle frontal −0.034 0.012 2.82 .007
Right rostral middle frontal −0.030 0.011 2.82 .007
Left superior frontal −0.026 0.013 2.08 .045
Right superior frontal −0.037 0.012 3.15 .003
Left frontal pole −0.047 0.034 1.38 .181
Right frontal pole −0.072 0.026 2.73 .009
Left insula −0.023 0.015 1.59 .123
Right insula −0.032 0.016 2.02 .051
Total brain −0.028 0.009 3.12 .003
Note: p-values < .05 are depicted in bold.
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